According to a recent LinkedIn post from Aignostics, company scientists Nina Kozar-Gillan, PhD, and Arne Schmidt are listed as collaborators on two research posters at the AACR 2026 conference. The work, led by Pfizer researchers, focuses on spatial and transcriptomic analysis of tumor microenvironments and novel quantitative frameworks for profiling immune heterogeneity.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post highlights involvement in a study on neoadjuvant atezolizumab in urothelial carcinoma (ABACUS) and a methodological advance called HPlot for spatial immune profiling. For investors, this suggests Aignostics is positioning its pathology and spatial analytics capabilities alongside major pharma partners, which could enhance its credibility, support future collaborations, and potentially expand its role in cancer drug development workflows.
The reference to an Aignostics booth at AACR indicates active business development efforts targeting oncology and translational research stakeholders. While no commercial milestones or revenues are mentioned, consistent visibility at leading oncology conferences may help strengthen the company’s pipeline of partnerships and validate its technology stack in high-value immuno-oncology applications.